HK1053975A1 - Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan - Google Patents

Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan

Info

Publication number
HK1053975A1
HK1053975A1 HK03106060A HK03106060A HK1053975A1 HK 1053975 A1 HK1053975 A1 HK 1053975A1 HK 03106060 A HK03106060 A HK 03106060A HK 03106060 A HK03106060 A HK 03106060A HK 1053975 A1 HK1053975 A1 HK 1053975A1
Authority
HK
Hong Kong
Prior art keywords
thalidomide
irinotecan
treatment
colorectal cancer
compositions
Prior art date
Application number
HK03106060A
Other languages
English (en)
Inventor
Rangaswamy Govindarajan
Andrew Zeitlin
Original Assignee
Celgene Corp
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Univ Arkansas filed Critical Celgene Corp
Publication of HK1053975A1 publication Critical patent/HK1053975A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03106060A 2000-05-15 2003-08-23 Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan HK1053975A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20414200P 2000-05-15 2000-05-15
PCT/US2001/015326 WO2001087306A2 (en) 2000-05-15 2001-05-10 Compositions and methods for the treatment of colorectal cancer

Publications (1)

Publication Number Publication Date
HK1053975A1 true HK1053975A1 (en) 2003-11-14

Family

ID=22756801

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03106060A HK1053975A1 (en) 2000-05-15 2003-08-23 Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan

Country Status (13)

Country Link
US (2) US6914067B2 (es)
EP (1) EP1286671B1 (es)
JP (1) JP4679028B2 (es)
AT (1) ATE322265T1 (es)
AU (2) AU2001261473B2 (es)
CA (1) CA2408710C (es)
DE (1) DE60118547T2 (es)
DK (1) DK1286671T3 (es)
ES (1) ES2261415T3 (es)
HK (1) HK1053975A1 (es)
NZ (1) NZ522766A (es)
PT (1) PT1286671E (es)
WO (1) WO2001087306A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2005504759A (ja) * 2001-07-23 2005-02-17 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト Ｃｙｐ３ａ５に基づいたがんの改善治療の手段及び方法
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) * 2002-11-14 2015-04-14 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US6987012B2 (en) * 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
AP2006003637A0 (en) * 2003-11-06 2006-06-30 Celgene Corp Methods and compositions using thalidomide for thetreatment and management of cancers and other diseases
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP1746976B1 (en) 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
CA2503099A1 (en) * 2005-04-18 2006-10-18 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
CN101180061A (zh) * 2005-05-19 2008-05-14 普罗米蒂克生物科学公司 化合物、含有此类化合物的组合物、和治疗转移性黑素瘤和其它癌症的方法
KR20080066663A (ko) * 2005-09-21 2008-07-16 씨씨씨 디아그노스틱스 엘엘씨 맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법
US20070219825A1 (en) * 2005-11-23 2007-09-20 Maetzold Derek J Method of managing and reducing side effects associated with exposure to a drug
US7723301B2 (en) * 2007-08-29 2010-05-25 The Board Of Trustees Of The University Of Arkansas Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HRP20230265T1 (hr) 2014-08-22 2023-04-14 Celgene Corporation Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
AU2016310476B8 (en) 2015-08-21 2021-10-07 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
MA42991A (fr) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd Stabilisation de compositions pharmaceutiques de camptothécine
ES2968415T3 (es) 2016-02-09 2024-05-09 Sun Pharmaceutical Ind Ltd Sistema de perfusión
JP2019533684A (ja) 2016-11-02 2019-11-21 イプセン バイオファーム リミティド リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN116333154A (zh) * 2019-08-19 2023-06-27 美勒斯公司 用结合lgr5和egfr的抗体与拓扑异构酶i抑制剂的组合治疗癌症

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US5955466A (en) * 1997-02-27 1999-09-21 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea

Also Published As

Publication number Publication date
US6914067B2 (en) 2005-07-05
WO2001087306A8 (en) 2002-10-03
DK1286671T3 (da) 2006-07-17
US20020035091A1 (en) 2002-03-21
EP1286671A2 (en) 2003-03-05
PT1286671E (pt) 2006-08-31
JP4679028B2 (ja) 2011-04-27
EP1286671B1 (en) 2006-04-05
JP2003533483A (ja) 2003-11-11
DE60118547T2 (de) 2007-02-01
AU2001261473B2 (en) 2006-09-14
CA2408710A1 (en) 2001-11-22
US20050203060A1 (en) 2005-09-15
US7479499B2 (en) 2009-01-20
WO2001087306A2 (en) 2001-11-22
ATE322265T1 (de) 2006-04-15
NZ522766A (en) 2005-09-30
ES2261415T3 (es) 2006-11-16
DE60118547D1 (de) 2006-05-18
CA2408710C (en) 2010-01-26
AU6147301A (en) 2001-11-26

Similar Documents

Publication Publication Date Title
HK1053975A1 (en) Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
MXPA02011218A (es) Composiciones y metodos para el tratamiento de cancer.
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
PL368971A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
MXPA04001398A (es) Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo.
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
EP1381378A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER FROM INULA BRITANNICA
GB0020504D0 (en) Therapeutic method
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2003014128A3 (de) Tumorhemmende cerverbindungen
WO2001074341A3 (en) Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
UA43257A (uk) Спосіб лікування критичної ішемії нижніх кінцівок
WO2003000182A3 (en) Ppar-alpha ligands for the treatment or prevention of cachexia
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer
UA36251A (uk) Спосіб комплексної терапії простої шизофренії
UA33545A (uk) Спосіб лікування дакріоциститу
UA32314A (uk) Спосіб лікування некротичного панкреатиту

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150510